Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.
- 15 November 1992
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 89 (22) , 10892-10895
- https://doi.org/10.1073/pnas.89.22.10892
Abstract
We have explored the use of primary myoblasts as a somatic tissue for gene therapy of acquired and inherited diseases where systemic delivery of a gene product may have therapeutic effects. Mouse primary myoblasts were infected with replication-defective retroviruses expressing canine factor IX cDNA under the control of a mouse muscle creatine kinase enhancer and human cytomegalovirus promoter. The infected myoblasts were injected into the hindlegs of recipient mice and levels of secreted factor IX protein were monitored in the plasma. We report sustained expression of factor IX protein for over 6 months without any apparent adverse effect on the recipient mice.Keywords
This publication has 21 references indexed in Scilit:
- Human gene therapy comes of ageNature, 1992
- Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscleSomatic Cell and Molecular Genetics, 1992
- Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered MyoblastsScience, 1991
- Migration of myoblasts across basal lamina during skeletal muscle developmentNature, 1990
- Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.Proceedings of the National Academy of Sciences, 1989
- Cationic liposome-mediated RNA transfection.Proceedings of the National Academy of Sciences, 1989
- Progress Toward Human Gene TherapyScience, 1989
- Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblastsNature, 1989
- Normal myoblast injections provide genetic treatment for murine dystrophyMuscle & Nerve, 1988
- An alternative approach to somatic cell gene therapy.Proceedings of the National Academy of Sciences, 1988